Formulation and Evaluation of Sustained-Release Tablets of a Cardiovascular Drug

Project Abstract

This project aims to develop and evaluate sustained-release tablets of a cardiovascular drug, addressing the need for improved therapeutic management and patient compliance in the treatment of cardiovascular diseases. Cardiovascular disorders, such as hypertension, angina, and heart failure, are among the leading causes of morbidity and mortality worldwide, necessitating the development of effective and patient-friendly medication delivery systems. Conventional immediate-release formulations of cardiovascular drugs often require multiple daily doses, leading to fluctuations in plasma drug levels and the potential for adverse effects. Sustained-release formulations, on the other hand, can provide a more consistent and prolonged drug release profile, thereby enhancing therapeutic efficacy, reducing adverse events, and improving patient adherence to the treatment regimen. The primary objective of this project is to formulate and evaluate sustained-release tablets of a cardiovascular drug, utilizing various sustained-release techniques and excipients. The project will involve a thorough investigation of the physicochemical properties of the drug, the selection of appropriate polymers and other excipients, and the optimization of the tablet formulation to achieve the desired drug release profile. The project will commence with a comprehensive literature review to identify the current state of the art in sustained-release formulations of cardiovascular drugs, as well as to gather information on the specific drug selected for this study. This will be followed by the development of a suitable analytical method for the quantification of the drug in the formulations. The next phase will focus on the formulation development, where various strategies, such as matrix systems, membrane-controlled systems, and osmotic pumps, will be explored to achieve the desired sustained-release characteristics. Excipients like hydrophilic and hydrophobic polymers, pore-forming agents, and release-modifying agents will be evaluated for their impact on drug release kinetics. The formulated sustained-release tablets will undergo a comprehensive in vitro evaluation, including tests for physical properties (hardness, friability, thickness, and weight variation), drug content, and in vitro drug release studies. The in vitro release profiles will be analyzed using various kinetic models to understand the drug release mechanisms and to optimize the formulation. Based on the in vitro performance, the most promising sustained-release tablet formulation will be selected for further evaluation. This will include stability studies under different storage conditions to assess the long-term performance and robustness of the formulation. The successful completion of this project will result in the development of a stable, effective, and patient-friendly sustained-release tablet formulation of the cardiovascular drug. The findings of this study will contribute to the advancement of drug delivery systems for the management of cardiovascular diseases, potentially leading to improved therapeutic outcomes and enhanced patient quality of life. The potential impact of this project extends beyond the immediate formulation development, as the insights gained can be applied to the design of sustained-release delivery systems for other cardiovascular drugs or even medications for other therapeutic areas. Furthermore, the knowledge and expertise acquired during this project can be utilized to foster future research and development in the field of controlled-release drug delivery.

Project Overview